After SenoRx, Inc. (NASDAQ:SENO) announced to be acquired by C. R. Bard an investigation on behalf of current investors in SenoRx, Inc. (NASDAQ:SENO) concerning shareholder claims over possible breaches of fiduciary duty was announced.

The investigation by a law firm focuses on potential breaches of fiduciary duty and other violations of state law by the Board of Directors of SenoRx arising out of their attempt to sell SenoRx, Inc. (NASDAQ:SENO) to C. R. Bard. SenoRx, Inc., located in Aliso Viejo, California, develops, manufactures and sells medical devices that are used in the diagnosis and treatment of breast cancer. SenoRx, Inc. reported in 2007 Total Revenue of $35.04million, in 2008 $46.69million, and in 2009 $55.58million.

On, Wednesday, May 05, 2010, SenoRx, Inc. (Nasdaq:SENO) announced it has entered into a merger agreement with C. R. Bard (NYSE:BCR) at a price of $11 per share, or approximately $213 million in the aggregate. According to SenoRx its board of directors unanimously approved the agreement and the offer represents a 14 percent premium over the closing price on May 4, 2010 and a 41 percent premium over the company's average closing price during the 90 trading days ended May 4, 2010.

Shares of SenoRx, Inc. (SENO) traded at $11.01 per share after the announcement, and at $9.97 per share just days before the news.

The investigation by a law firm concerns whether the SenoRx Board of Directors breached their fiduciary duties to SenoRx, Inc. (NASDAQ:SENO) stockholders by failing to adequately shop the Company prior to entering into the agreement, whether the Board of Directors breached their fiduciary duties by not seeking a deal that would provide better value SenoRx, Inc., and whether C. R. Bard is underpaying for SenoRx, Inc. (SENO), thus unlawfully harming:SENO stockholders.